How to Cite
Abstract
Colorectal cancer is closely related to changes in the immune status at all stages of the disease. The main method of treatment for colorectal cancer is surgery. Surgical intervention as any pathological impact on the body from the outside is leading to suppression of both humoral and cellular immunity. Melatonin can be used to stimulate the immune system acting as a protective agent. Currently melatonin is used in oncology practice rather modest - as part of a complex postoperative therapy. Melatonin in pharmaceutical concentrations acts as differentiation factor reducing infiltrative and metastatic potential by restoring the links between signaling molecules and inhibiting existing cell-cell contacts, which can be used in the preoperative therapy.References
Анисимов В.Н., Кветной И.М., Комаров Ф.М. и др. Мелатонин в физиологии и патологии желудочно-кишечного тракта // Москва: Советский спорт - 2000. -183 с.
Ермаченков М.Н., Гуляев А.В., Анисимов В.Н. Мелатонин и рак толстой кишки: повышение эффективности стандартного лечения // Вестн. Сев.-зап. гос. мед. унив. им. И.И. Мечникова. - 2012. - Т. 4. - N 1. - C. 78-83.
Мазуркевич Г.С., Багненко С.Ф. Шок: теория, клиника, организация противошоковой помощи // СПБ: Политехника. - 2004. - С.36-38,117.
Манчева Т.А., Демидов Д.В., Плотникова Н.А. и др. Мелатонин и метформин угнетают канцерогенез кожи и перекисное окисление липидов, индуцируемые бенз(а)пиреном у самок мышей // Бюлл. эксперимент. Биол. и мед. - 2011. - N 3. - С. 339-342.
Anisimov V.N., Popovich I.G., Zabezhinski M.A. et al. Melatonin as antioxidant, geroprotector and anticarcinogen // Biochim Biophys Acta. -2006 -Vol. 1757(5-6). - P. 573-589.
Asselin-Paturel C., Megherat S., Vergnon I. et al. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-non obese diabetic mice: relation with interleukin-10 induction // Cancer 2001. - Vol. 91. - P. 113-122.
Bartsch C.,H. Bartsch H., Blask D.E. et al. The Pineal Gland and Cancer: Neuroimmunoendocrine Mechanisms in Malignancy // Berlin: Springer Science & Business Media - 2012. - 578 р.
Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy // Curr Top Med Chem. - 2002. - Vol. 2 (2). - P. 113-132.
Btaiche I.F., Chan L.N., Pliva M., Kraft M.D. Critical illness,gastrointestinal complications, and medication therapy during enteral feeding in critically ill adult patients // Nutr Clin Pract. - 2010. - Vol. 25. - №1. - P. 32-39.
Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. // Endocrine. - 2005. - Vol. 27 (2). -P. 189-200.
Dalgleish A.G., O’Byrne K.J. Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer // Adv Cancer Res. - 2002. - Vol. 84. - P. 231-276.
De Vita F., Orditura M., Galizia G. et al. Serum interleukin-10 is an independent prognostic factor in advanced solid tumors// Oncol Rep. - 2000. - Vol. 7. - P. 357-361.
Galizia G, Lieto E, De Vita F. et al. Circulating levels of interleukin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome // J Interferon Cytokine Res. - 2002. - Vol. 22. - P. 473-482.
Galizia G., Orditura M., Romano C. et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery // Clin Immunol. -2002. - Vol. 102. - P. 169-178.
Giacomelli L., Gianni W., Belfiore C.et al. Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse // Clin Cancer Res. - 2003. - Vol. 9. - P. 2678-2682.
Grunfeld C. Leptin and the immunosuppression of malnutrition // J Clin Endocrinol Metab. - 2002. - Vol. 87. - P. 3038-3039.
Herbeuval J.P., Lelievre E., Lambert C., Dy M., Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage derived IL-6.-//J Immunol. - 2004. - Vol. 172. - P. 4630-4636.
Heriot A.G., Marriott J.B., Cookson S. et al. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection // Br J Cancer. - 2000. - Vol. 82. - P. 1009-1012.
Hobday T.J. An overview of approaches to adjuvant therapy for colorectal cancer in the United States // Clin Colorectal Cancer. - 2005. - N5 (Suppl. 1). - P. S11-18.
Jessup J.M., Samara R., Battle P., Laguinge L.M. Carcinoembryonic antigen promotes tumor cell survival in liver through an IL-10-dependent pathway // Clin Exp Metastasis. - 2004. - Vol. 21. - P. 709-717.
Kanazawa M, Yoshihara K, Abe H. et al. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients // Anticancer Res. - 2005. -Vol. 25. - P. 443-449.
Kim J., Modlin R.L., Moy R.L. etal. IL-10production in cutaneous basal and squamous cells carcinomas.A mechanism for evading the lokal T-cells immune response // J Immunol. - 1995. - Vol. 155. - P. 2240-2247.
Lissoni P., Brivio F., Brivio O. et al. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients// J Biol Regul Homeost Agents. - 1995. - Vol. 9 (1). - P. 31-33.
Lissoni P., Rovelli F., Brivio F., Fumagalli L., Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients // In Vivo. - 2008. - Vol. 22 (3). - P. 397-400.
Maestroni G.J. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer // Adv Exp Med Biol.- 1999. - Vol. 467. - P. 217-226.
Mancheva T.A., Anisimov V.N. Melatonin and metformin inhibit skin cancerogenesis and lipid peroxidationinduced by benz(a)pyren in femail mice // Bull Exp Biol Med. -2011. - Vol. 151 (3). - P. 363-365.
Matsuda M, Salazar F, Petersson M. et al.Interleukin 10 pretreatment protects target cells from tumor- and allospecific cytotoxic T cells and downregulates HLA class I expression// J Exp Med. - 1994. - Vol. 180. - P. 2371-2376.
Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer.// N EnglJ Med. - 2005. - Vol. 352. - P. 476-487.
McCarty M.F. Zinc and multi-mineral supplementation should mitigate the pathogenic impact of cadmium exposure // Med Hypotheses. - 2012. -Vol. 79 (5). -P. 642-648.
Nakayama H., Kitayama J., Muto T., Nagawa H. Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer //Jpn J Clin Oncol. - 2000. - Vol. 30. - P. 301-305.
O’Hara R.J., Greenman J., MacDonald A.W. et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production // Clin Cancer Res. - 1998. - Vol. 4. - P. 1943-1948.
Ordemann J., Jacobi C.A., Braumann C.et al. Immunomodulatory changes in patients with colorectal cancer// Int J Colorectal Dis. - 2002. - Vol. 17. - P. 37-41.
Pawelec G., Barnett Y., Forsey R. et al. T cells and aging, January 2002 update// Front Biosci. - 2002. - Vol. 7. - P. d 1056-1183.
Pellegrini P., Berghella A.M., Del Beato T. et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression // Cancer Immunol Immunother. - 1996. - Vol. 42. - P. 1-8.
Penland S.K., Goldberg R.M. Current strategies in previously untreated advanced colorectal cancer // Oncology. - 2004. - Vol. 18. - P. 715-722.
Pliss M. First experience on preoperational treatment colon cancer patients by Melatonin// World Congress for Advancement of Surgery. - 2013. - Tel Aviv Congress materials. -P. 23
Pliss M.M., Pliss M.G. Enchancing recovery period in patients with colon cancer by Melatonin preconditioning // ERAS(Enchancing recovery after surgery) Society congress. - 2014. - Congress materials. - Valencia, Spain. - 2014. - P. 45.
Reiter R.J., Tan D.X., Manchester L.C. et al. Medical implications of melatonin: Receptor-mediated and receptor-independent actions // Adv Med Sci. - 2007. - Vol. 52. - P. 11-28.
Salazar-Onfray F/, Charo J., Petersson M. et al. Down regulation of the expressionand function of the transporter assosiated with antigen processingin murine tumor cell lines, expressing IL-10 // J Immunol. - 1997. - Vol. 159. - P. 3195-3202.
Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser phosphorylation and prevents DNA-damage accumulation // Oncogene. - 2012. -Vol. 31 (24). - P. 2931-2942.
Shibata M, Nezu T, Kanou H. et al.Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer// J Clin Gastroenterol. - 2002. - Vol. 34. - P. 416-420.
Shirazi A, Ghobadi G, Ghazi-Khansari M. A radiobiological review on melatonin: a novel radioprotector // J Radiat Res. - 2007. - Vol. 48 (4). - P. 263-272.
Siegel R., Ward E., Brawley O. et al. Cancer Statistics, 2011: The impact of eliminating socioeconomic and racial disparties on premature cancer death // CA Cancer J Clin. - 2011. - Vol. 61. - P. 212.
Waterhouse J., Reilly T., Atkinson G., Edvards B. Jet Lag :Trends and coping strategies // Lancet. - 2007. - Vol. 369. - P. 1117-1129.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...